Free Trial

Cingulate (CING) Competitors

Cingulate logo
$4.34 -0.17 (-3.77%)
Closing price 02/18/2025 03:58 PM Eastern
Extended Trading
$4.53 +0.19 (+4.38%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CING vs. ALXO, LTRN, PDSB, IMMX, OTLK, VNRX, STTK, ATRA, RPTX, and CNTB

Should you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include ALX Oncology (ALXO), Lantern Pharma (LTRN), PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Outlook Therapeutics (OTLK), VolitionRx (VNRX), Shattuck Labs (STTK), Atara Biotherapeutics (ATRA), Repare Therapeutics (RPTX), and Connect Biopharma (CNTB). These companies are all part of the "pharmaceutical products" industry.

Cingulate vs.

ALX Oncology (NASDAQ:ALXO) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

ALX Oncology received 42 more outperform votes than Cingulate when rated by MarketBeat users. However, 76.92% of users gave Cingulate an outperform vote while only 64.20% of users gave ALX Oncology an outperform vote.

CompanyUnderperformOutperform
ALX OncologyOutperform Votes
52
64.20%
Underperform Votes
29
35.80%
CingulateOutperform Votes
10
76.92%
Underperform Votes
3
23.08%

In the previous week, Cingulate had 2 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Cingulate and 1 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.51 beat Cingulate's score of 0.25 indicating that ALX Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALX Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cingulate
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ALX Oncology has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.84, meaning that its stock price is 184% less volatile than the S&P 500.

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 33.4% of ALX Oncology shares are owned by insiders. Comparatively, 17.1% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ALX Oncology presently has a consensus target price of $3.05, suggesting a potential upside of 157.38%. Cingulate has a consensus target price of $16.00, suggesting a potential upside of 268.66%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than ALX Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALX Oncology
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Cingulate
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

ALX Oncology's return on equity of -93.02% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
ALX OncologyN/A -93.02% -70.67%
Cingulate N/A -570.20%-236.15%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALX OncologyN/AN/A-$160.80M-$2.98-0.40
CingulateN/AN/A-$23.53MN/AN/A

Summary

ALX Oncology beats Cingulate on 7 of the 13 factors compared between the two stocks.

Get Cingulate News Delivered to You Automatically

Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CING vs. The Competition

MetricCingulatePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$14.49M$6.89B$5.81B$9.23B
Dividend YieldN/A2.89%5.25%3.99%
P/E RatioN/A2.9216.7814.85
Price / SalesN/A322.14469.7179.60
Price / CashN/A73.0244.9938.25
Price / Book-0.065.567.195.01
Net Income-$23.53M$161.53M$3.20B$236.25M
7 Day Performance-3.98%1.73%1.34%2.13%
1 Month Performance-8.82%1.38%3.43%1.63%
1 Year Performance274.14%-0.12%20.43%16.41%

Cingulate Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CING
Cingulate
3.4576 of 5 stars
$4.34
-3.8%
$16.00
+268.7%
+274.1%$14.49MN/A0.0020
ALXO
ALX Oncology
3.7054 of 5 stars
$1.04
-4.6%
$3.05
+193.3%
-92.5%$54.85MN/A-0.3540
LTRN
Lantern Pharma
0.3998 of 5 stars
$5.05
-0.4%
N/A+9.9%$54.44MN/A-2.8420Gap Up
PDSB
PDS Biotechnology
1.3046 of 5 stars
$1.45
-0.7%
$11.67
+704.6%
-73.7%$54.24MN/A-1.2520
IMMX
Immix Biopharma
2.7171 of 5 stars
$1.97
-2.0%
$7.00
+255.3%
-39.5%$54.20MN/A-2.329Gap Down
High Trading Volume
OTLK
Outlook Therapeutics
2.0092 of 5 stars
$1.69
-1.2%
$27.40
+1,521.3%
-81.1%$54.05MN/A-0.1920Earnings Report
Analyst Forecast
News Coverage
VNRX
VolitionRx
2.1686 of 5 stars
$0.58
-3.3%
$3.75
+546.6%
-41.7%$53.75M$770,000.00-1.6180Analyst Forecast
STTK
Shattuck Labs
3.703 of 5 stars
$1.12
-5.1%
$8.67
+673.8%
-86.9%$53.47M$1.66M-0.73100News Coverage
ATRA
Atara Biotherapeutics
4.2182 of 5 stars
$9.26
-8.0%
$17.75
+91.7%
-57.5%$53.34M$8.57M-0.36330
RPTX
Repare Therapeutics
3.1396 of 5 stars
$1.20
flat
$7.00
+483.3%
-80.7%$51.01M$51.13M-0.60180Upcoming Earnings
News Coverage
CNTB
Connect Biopharma
3.7519 of 5 stars
$0.92
-6.6%
$8.00
+768.9%
-30.0%$50.87MN/A0.00110

Related Companies and Tools


This page (NASDAQ:CING) was last updated on 2/19/2025 by MarketBeat.com Staff
From Our Partners